Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. DOI: 10.1097/HEP.0000000000000520.
DOI: 10.1097/HEP.0000000000000520
ICD-11. International Classification of Diseases 11th Revision. URL: https://icd.who.inthttps://icd.who.int
ICD-11. International Classification of Diseases 11th Revision. URL: https://icd.who.inthttps://icd.who.int
Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.e1–9. DOI: 10.1016/j.cgh.2014.04.014.
DOI: 10.1016/j.cgh.2014.04.014
Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А. и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35–44. DOI: 10.22416/1382-4376-2024-961.
DOI: 10.22416/1382-4376-2024-961
Day C.P., James O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842–5. DOI: 10.1016/s0016-5085(98)70599-2.
DOI: 10.1016/s0016-5085(98)70599-2
Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(Suppl. 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012.
DOI: 10.1016/j.jhep.2014.12.012
Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: Shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134(1):8–19. DOI: 10.1097/CM9.0000000000001263.
DOI: 10.1097/CM9.0000000000001263
Parthasarathy G., Revelo X., Malhi H. Pathogenesis of nonalcoholic steatohepatitis: An overview. Hepatol Commun. 2020;4(4):478–92. DOI: 10.1002/hep4.1479.
DOI: 10.1002/hep4.1479
Haas J.T., Francque S., Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. DOI: 10.1146/annurev-physiol-021115-105331.
DOI: 10.1146/annurev-physiol-021115-105331
Basaranoglu M., Basaranoglu G., Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4(2):109–16. DOI: 10.3978/j.issn.2304-3881.2014.11.05.
DOI: 10.3978/j.issn.2304-3881.2014.11.05
Jensen T., Abdelmalek M.F., Sullivan S., Nadeau K.J., Green M., Roncal C., et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063–75. DOI: 10.1016/j.jhep.2018.01.019.
DOI: 10.1016/j.jhep.2018.01.019
Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713–23. DOI: 10.1002/hep.26672.
DOI: 10.1002/hep.26672
Ipsen D.H., Lykkesfeldt J., Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–27. DOI: 10.1007/s00018-018-2860-6.
DOI: 10.1007/s00018-018-2860-6
Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–35. DOI: 10.1053/j.gastro.2013.11.049.
DOI: 10.1053/j.gastro.2013.11.049
Ter Horst K.W., Serlie M.J. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):981. DOI: 10.3390/nu9090981.
DOI: 10.3390/nu9090981
Shen J., Sakaida I., Uchida K., Terai S., Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci. 2005;77(13):1502–15. DOI: 10.1016/j.lfs.2005.04.004.
DOI: 10.1016/j.lfs.2005.04.004
Subichin M., Clanton J., Makuszewski M., Bohon A., Zografakis J.G., Dan A. Liver disease in the morbidly obese: A review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137–41. DOI: 10.1016/j.soard.2014.06.015.
DOI: 10.1016/j.soard.2014.06.015
Sasaki A., Nitta H., Otsuka K., Umemura A., Baba S., Obuchi T., et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164. DOI: 10.3389/fendo.2014.00164.
DOI: 10.3389/fendo.2014.00164
Stojsavljević S., Gomerčić Palčić M., Virović Jukić L., Smirčić Duvnjak L., Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–91. DOI: 10.3748/wjg.v20.i48.18070.
DOI: 10.3748/wjg.v20.i48.18070
Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363–74. DOI: 10.1038/nm.2627.
DOI: 10.1038/nm.2627
Yan F.J., Wang X., Wang S.E., Hong H.T., Lu J., Ye Q., et al. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochem J. 2020;477(3):691–708. DOI: 10.1042/BCJ20190799.
DOI: 10.1042/BCJ20190799
Jin S., Li Y., Xia T., Liu Y., Zhang S., Hu H., et al. Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease. J Adv Res. 2025:67:317–29. DOI: 10.1016/j.jare.2024.01.027.
DOI: 10.1016/j.jare.2024.01.027
Prerna K., Dubey V.K. Beclin1-mediated interplay between autophagy and apoptosis: New understanding. Int J Biol Macromol. 2022;204:258–73. DOI: 10.1016/j.ijbiomac.2022.02.005.
DOI: 10.1016/j.ijbiomac.2022.02.005
Fromenty B., Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol. 2023;78(2):415–29. DOI: 10.1016/j.jhep.2022.09.020.
DOI: 10.1016/j.jhep.2022.09.020
Ferré P., Foufelle F. SREBP-1c transcription factor and lipid homeostasis: Clinical perspective. Horm Res. 2007;68(2):72–82. DOI: 10.1159/000100426.
DOI: 10.1159/000100426
Miserez A.R., Muller P.Y., Barella L., Barella S., Staehelin H.B., Leitersdorf E., et al. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis. 2002;164(1):15–26. DOI: 10.1016/s0021-9150(01)00762-6.
DOI: 10.1016/s0021-9150(01)00762-6
Iizuka K., Takao K., Yabe D. ChREBP-mediated regulation of lipid metabolism: Involvement of the gut microbiota, liver, and adipose tissue. Front Endocrinol (Lausanne). 2020;11:587189. DOI: 10.3389/fendo.2020.587189.
DOI: 10.3389/fendo.2020.587189
Ma M., Xie W., Li X. Identification of autophagy-related genes in the progression from non-alcoholic fatty liver to non-alcoholic steatohepatitis. Int J Gen Med. 2021;14:3163–76. DOI: 10.2147/IJGM.S317785.
DOI: 10.2147/IJGM.S317785
Barrientos-Riosalido A., Real M., Bertran L., Aguilar C., Martínez S., Parada D., et al. Increased hepatic ATG7 mRNA and ATG7 protein expression in nonalcoholic steatohepatitis associated with obesity. Int J Mol Sci. 2023;24(2):1324. DOI: 10.3390/ijms24021324.
DOI: 10.3390/ijms24021324
Syed-Abdul M.M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites. 2023;14(1):12. DOI: 10.3390/metabo14010012.
DOI: 10.3390/metabo14010012
Branković M., Dukić M., Gmizić T., Popadić V., Nikolić N., Sekulić A., et al. New therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. DOI: 10.3390/diagnostics14020229.
DOI: 10.3390/diagnostics14020229
Zhao Y., Zhou Y., Wang D., Huang Z., Xiao X., Zheng Q., et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. DOI: 10.3390/ijms242417514.
DOI: 10.3390/ijms242417514
Chen Z., Tian R., She Z., Cai J., Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116–41. DOI: 10.1016/j.freeradbiomed.2020.02.025.
DOI: 10.1016/j.freeradbiomed.2020.02.025
Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753–66. DOI: 10.1038/nri2858.
DOI: 10.1038/nri2858
Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60–81. DOI: 10.1111/j.1600-065X.2007.00579.x.
DOI: 10.1111/j.1600-065X.2007.00579.x
Szabo G., Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642–54. DOI: 10.1016/j.jhep.2012.03.035.
DOI: 10.1016/j.jhep.2012.03.035
Luedde T., Schwabe R.F. NF-κB in the liver — linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–18. DOI: 10.1038/nrgastro.2010.213.
DOI: 10.1038/nrgastro.2010.213
Klein I., Cornejo J.C., Polakos N.K., John B., Wuensch S.A., Topham D.J., et al. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic macrophages. Blood. 2007;110(12):4077–85. DOI: 10.1182/blood-2007-02-073841.
DOI: 10.1182/blood-2007-02-073841
Fang Y.L., Chen H., Wang C.L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol. 2018;24(27):2974–83. DOI: 10.3748/wjg.v24.i27.2974.
DOI: 10.3748/wjg.v24.i27.2974
Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55(3):415–24. DOI: 10.1136/gut.2005.071118.
DOI: 10.1136/gut.2005.071118
Kremer M., Hines I.N., Milton R.J., Wheeler M.D. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology. 2006;44(1):216–27. DOI: 10.1002/hep.21221.
DOI: 10.1002/hep.21221
Ghazarian M., Revelo X.S., Nøhr M.K., Luck H., Zeng K., Lei H., et al. Type I interferon Responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017;2(10):eaai7616. DOI: 10.1126/sciimmunol.aai7616.
DOI: 10.1126/sciimmunol.aai7616
Wang M., Li L., Xu Y., Du J., Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol. 2022;13:958428. DOI: 10.3389/fphar.2022.958428.
DOI: 10.3389/fphar.2022.958428
Li Z., Yuan H., Chu H., Yang L. The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease. Microorganisms. 2023;11(8):2059. DOI: 10.3390/microorganisms11082059.
DOI: 10.3390/microorganisms11082059
Clemente M.G., Mandato C., Poeta M., Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016;22(36):8078–93. DOI: 10.3748/wjg.v22.i36.8078.
DOI: 10.3748/wjg.v22.i36.8078
Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769–76. DOI: 10.3945/jn.110.135657.
DOI: 10.3945/jn.110.135657
Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(42):15518–31. DOI: 10.3748/wjg.v20.i42.15518.
DOI: 10.3748/wjg.v20.i42.15518
Zorn A.M., Wells J.M. Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 2009;25:221–51. DOI: 10.1146/annurev.cellbio.042308.113344.
DOI: 10.1146/annurev.cellbio.042308.113344
Fairfield C.J., Drake T.M., Pius R., Bretherick A.D., Campbell A., Clark D.W., et al. Genome-wide association study of NAFLD using electronic health records. Hepatol Commun. 2022;6(2):297–308. DOI: 10.1002/hep4.1805.
DOI: 10.1002/hep4.1805
Anstee Q.M., Darlay R., Cockell S., Meroni M., Govaere O., Tiniakos D., et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020;73(3):505–15. DOI: 10.1016/j.jhep.2020.04.003.
DOI: 10.1016/j.jhep.2020.04.003
Куртанов Х.А., Сыдыкова Л.А., Павлова Н.И., Филиппова Н.П., Додохов В.В., Апсолихова Г.А. и др. Полиморфизм гена адипонутрина (PNPLA3) у коренных жителей Республики Саха (Якутия), страдающих сахарным диабетом 2-го типа. Альманах клинической медицины. 2018;46(3):258–63. DOI: 10.18786/2072-0505-2018-46-3-258-263.
DOI: 10.18786/2072-0505-2018-46-3-258-263
Кролевец Т.С., Ливзан М.А., Ахмедов В.А., Новиков Д.Г. Исследование полиморфизма гена PNPLA3 у пациентов с неалкогольной жировой болезнью печени и различной стадией фиброза. Экспериментальная и клиническая гастроэнтерология. 2018;11:24–32.
Райхельсон К.Л., Ковязина В.П., Сидоренко Д.В., Назаров В.Д., Лапин С.В., Эмануэль В.Л. и др. Влияние полиморфизма гена PNPLA3 на течение неалкогольной жировой болезни печени. РМЖ. 2019;12:85–8.
Дьяконова А.Т., Куртанов Х.А., Павлова Н.И., Соловьева Н.А., Соловьева Ю.А., Филиппова Н.П. и др. Полиморфизм rs58542926 гена TM6SF2 при хронических неинфекционных болезнях печени в якутской популяции. Современные проблемы науки и образования. 2019;6:133. DOI: 10.17513/spno.29334.
DOI: 10.17513/spno.29334
Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–62. DOI: 10.1016/j.eprac.2022.03.010.
DOI: 10.1016/j.eprac.2022.03.010
Lonardo A., Ballestri S., Mantovani A., Nascimbeni F., Lugari S., Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig Liver Dis. 2019;51(4):462–70. DOI: 10.1016/j.dld.2018.12.014.
DOI: 10.1016/j.dld.2018.12.014
Ramanathan R., Patwa S.A., Ali A.H., Ibdah J.A. Thyroid hormone and mitochondrial dysfunction: Therapeutic implications for metabolic dysfunction-associated steatotic liver disease (MASLD). Cells. 2023;12(24):2806. DOI: 10.3390/cells12242806.
DOI: 10.3390/cells12242806
Younossi Z.M., Henry L. Understanding the burden of nonalcoholic fatty liver disease: Time for action. Diabetes Spectr. 2024;37(1):9–19. DOI: 10.2337/dsi23-0010.
DOI: 10.2337/dsi23-0010
Jichitu A., Bungau S., Stanescu A.M.A., Vesa C.M., Toma M.M., Bustea C., et al. Non-alcoholic fatty liver disease and cardiovascular comorbidities: Pathophysiological links, diagnosis, and therapeutic management. Diagnostics (Basel). 2021;11(4):689. DOI: 10.3390/diagnostics11040689.
DOI: 10.3390/diagnostics11040689
Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):32–8.
Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31–41.
Евстифеева С.Е., Шальнова С.А., Куценко В.А., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. DOI: 10.15829/1728-8800-2022-3356.
DOI: 10.15829/1728-8800-2022-3356
Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313–19. DOI: 10.26442/20751753.2023.5.202155.
DOI: 10.26442/20751753.2023.5.202155
Povsic M., Wong O.Y., Perry R., Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36(7):1574–94. DOI: 10.1007/s12325-019-00960-3.
DOI: 10.1007/s12325-019-00960-3
Harrison S.A., Gawrieh S., Roberts K., Lisanti C.J., Schwope R.B., Cebe K.M., et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284–91. DOI: 10.1016/j.jhep.2021.02.034.
DOI: 10.1016/j.jhep.2021.02.034
Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016– 2030. J Hepatol. 2018;69(4):896–904. DOI: 10.1016/j.jhep.2018.05.036.
DOI: 10.1016/j.jhep.2018.05.036
Huang D.Q., Terrault N.A., Tacke F., Gluud L.L., Arrese M., Bugianesi E., et al. Global epidemiology of cirrhosis — aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388–98. DOI: 10.1038/s41575-023-00759-2.
DOI: 10.1038/s41575-023-00759-2
Huang D.Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–38. DOI: 10.1038/s41575-020-00381-6.
DOI: 10.1038/s41575-020-00381-6
Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.В. и др. Цирроз и фиброз печени: клинические рекомендации. М.; 2021.
Muthiah M.D., Cheng Han N., Sanyal A.J. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications — What the non-specialist needs to know. Diabetes Obes Metab. 2022;24(Suppl. 2):3–14. DOI: 10.1111/dom.14521.
DOI: 10.1111/dom.14521
Cook N., Geier A., Schmid A., Hirschfield G., Kautz A., Schattenberg J.M., et al. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med (Lausanne). 2019;6:61. DOI: 10.3389/fmed.2019.00061.
DOI: 10.3389/fmed.2019.00061
Liebe R., Esposito I., Bock H.H., Vom Dahl S., Stindt J., Baumann U., et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74(6):1455–71. DOI: 10.1016/j.jhep.2021.01.045.
DOI: 10.1016/j.jhep.2021.01.045
Ивашкин В.Т. Пропедевтика внутренних болезней: учебник. 2-е изд. М.: ГЭОТАР-Медиа; 2023.
Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–40. DOI: 10.22416/1382-4376-2022-32-4-104-140.
DOI: 10.22416/1382-4376-2022-32-4-104-140
Obika M., Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. DOI: 10.1155/2012/145754.
DOI: 10.1155/2012/145754
Павлов Ч.С., Глушенков Д.В., Коновалова О.Н., Ивашкин В.Т. Сфера клинического применения неинвазивных методов оценки фиброза печени: результаты собственных исследований в многопрофильном стационаре. Клиническая медицина. 2009;87(11):40–5.
Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018–22. DOI: 10.1111/j.1572-0241.1999.01006.x.
DOI: 10.1111/j.1572-0241.1999.01006.x
Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2-го типа у взрослых: клинические рекомендации. М.; 2022.
Fujii H., Kawada N.; Japan Study Group Of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(11):3863. DOI: 10.3390/ijms21113863.
DOI: 10.3390/ijms21113863
Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. DOI: 10.1056/NEJMra0912063.
DOI: 10.1056/NEJMra0912063
Кутишенко Н.П., Марцевич С.Ю., Лерман О.В., Балашов И.С., Невзорова В.А., Резник И.И. и др. Повышение эффективности гиполипидемической терапии у пациентов высокого сердечно-сосудистого риска с сочетанной патологией печени (результаты дополнительного анализа исследования РАКУРС). Рациональная фармакотерапия в кардиологии. 2015;11(3):297–303. DOI: 10.20996/1819-6446-2015-11-3-297-303.
DOI: 10.20996/1819-6446-2015-11-3-297-303
Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена: клинические рекомендации. М.; 2023.
Spinosa M., Stine J.G. Nonalcoholic fatty liver disease — evidence for a thrombophilic state? Curr Pharm Des. 2020;26(10):1036–44. DOI: 10.2174/1381612826666200131101553.
DOI: 10.2174/1381612826666200131101553
Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121–9. DOI: 10.1002/hep.26510.
DOI: 10.1002/hep.26510
Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol. 2002;71(2):89–93. DOI: 10.1002/ajh.10192.
DOI: 10.1002/ajh.10192
Northup P.G., Argo C.K., Shah N., Caldwell S.H. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: Mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis. 2012;32(1):39–48. DOI: 10.1055/s-0032-1306425.
DOI: 10.1055/s-0032-1306425
Skurk T., Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28(11):1357–64. DOI: 10.1038/sj.ijo.0802778.
DOI: 10.1038/sj.ijo.0802778
Kotronen A., Joutsi-Korhonen L., Sevastianova K., Bergholm R., Hakkarainen A., Pietiläinen K.H., et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31(2):176–83. DOI: 10.1111/j.1478-3231.2010.02375.x.
DOI: 10.1111/j.1478-3231.2010.02375.x
Ciardullo S., Ballabeni C., Trevisan R., Perseghin G. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis. Biomolecules. 2022;12(1):105. DOI: 10.3390/biom12010105.
DOI: 10.3390/biom12010105
Sun D.Q., Jin Y., Wang T.Y., Zheng K.I., Rios R.S., Zhang H.Y., et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. DOI: 10.1016/j.metabol.2020.154433.
DOI: 10.1016/j.metabol.2020.154433
Бобкова И.Н., Ватазин А.В., Ветчинникова О.Н., Волгина Г.В., Голубев Р.В., Горелова Е.А. и др. Хроническая болезнь почек (ХБП): клинические рекомендации. М.; 2021.
Маевская М.В., Котовская Ю.В., Ивашкин В.Т., Ткачева О.Н., Трошина Е.А., Шестакова М.В. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–53. DOI: 10.26442/00403660.2022.02.201363.
DOI: 10.26442/00403660.2022.02.201363
Darmawan G., Hamijoyo L., Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A meta-analysis. Acta Med Indones. 2017;49(2):136–47.
Lombardi R., Pisano G., Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548. DOI: 10.3390/ijms17040548.
DOI: 10.3390/ijms17040548
Аверкина Н.А., Багаева М.Э., Батышева Т.Т., Быкова О.В., Вашакмадзе Н.Д., Волынец Г.В. и др. Нарушения обмена меди (болезнь Вильсона): клинические рекомендации. М.; 2021.
Ивашкин В.Т., Ющук Н.Д., Богомолов П.О., Волчкова Е.В., Дмитриев А.С., Жаркова М.С. и др. Хронический вирусный гепатит С: клинические рекомендации. М.; 2021.
Ивашкин В.Т., Маевская М.В., Жаркова М.С., Тихонов И.Н., Федосьина Е.А., Павлов Ч.С. Алгоритмы диагностики и лечения в гепатологии: справочные материалы. М.: МЕДпресс-информ; 2016.
Petzold G. Role of ultrasound methods for the assessment of NAFLD. J Clin Med. 2022;11(15):4581. DOI: 10.3390/jcm11154581.
DOI: 10.3390/jcm11154581
Ferraioli G., Soares Monteiro L.B. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62. DOI: 10.3748/wjg.v25.i40.6053.
DOI: 10.3748/wjg.v25.i40.6053
Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54(3):1082–90. DOI: 10.1002/hep.24452.
DOI: 10.1002/hep.24452
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J Hepatol. 2021;75(3):659–89. DOI: 10.1016/j.jhep.2021.05.025.
DOI: 10.1016/j.jhep.2021.05.025
Petroff D., Blank V., Newsome P.N., Shalimar, Voican C.S., Thiele M., et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–98. DOI: 10.1016/S2468-1253(20)30357-5.
DOI: 10.1016/S2468-1253(20)30357-5
Pu K., Wang Y., Bai S., Wei H., Zhou Y., Fan J., et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. DOI: 10.1186/s12876-019-0961-9.
DOI: 10.1186/s12876-019-0961-9
Gu J., Liu S., Du S., Zhang Q., Xiao J., Dong Q., et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol. 2019;29(7):3564–73. DOI: 10.1007/s00330-019-06072-4.
DOI: 10.1007/s00330-019-06072-4
Verhaegh P., Bavalia R., Winkens B., Masclee A., Jonkers D., Koek G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–61. DOI: 10.1016/j.cgh.2017.08.024.
DOI: 10.1016/j.cgh.2017.08.024
Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32(1):3–13. DOI: 10.1055/s-0032-1306421.
DOI: 10.1055/s-0032-1306421
Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701.
DOI: 10.1002/hep.20701
Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–75. DOI: 10.1002/hep.27173.
DOI: 10.1002/hep.27173
Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7(Suppl. 2):765–70. DOI: 10.1007/s12072-013-9446-z.
DOI: 10.1007/s12072-013-9446-z
Harrison S.A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485–90. DOI: 10.1111/j.1572-0241.2003.08699.x.
DOI: 10.1111/j.1572-0241.2003.08699.x
Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486–501. DOI: 10.1002/hep.29302.
DOI: 10.1002/hep.29302
McPherson S., Hardy T., Dufour J.F., Petta S., Romero-Gomez M., Allison M., et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–51. DOI: 10.1038/ajg.2016.453.
DOI: 10.1038/ajg.2016.453
Bril F., McPhaul M.J., Caulfield M.P., Clark V.C., Soldevilla-Pico C., Firpi-Morell R.J., et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43(2):290–7. DOI: 10.2337/dc19-1071.
DOI: 10.2337/dc19-1071
Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. DOI: 10.1186/1471-230X-6-6.
DOI: 10.1186/1471-230X-6-6
Vali Y., Lee J., Boursier J., Spijker R., Verheij J., Brosnan M.J., et al. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: A systematic review and meta-analysis. J Clin Med. 2021;10(11):2415. DOI: 10.3390/jcm10112415.
DOI: 10.3390/jcm10112415
Papatheodoridi M., Hiriart J.B., Lupsor-Platon M., Bronte F., Boursier J., Elshaarawy O., et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–16. DOI: 10.1016/j.jhep.2020.11.050.
DOI: 10.1016/j.jhep.2020.11.050
De Franchis R., Bosch J., Garcia-Tsao G., Reiberger T., Ripoll C. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. DOI: 10.1016/j.jhep.2021.12.022.
DOI: 10.1016/j.jhep.2021.12.022
World Health Organization. WHO guidelines on physical activity and sedentary behaviour. URL: https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdfhttps://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf
World Health Organization. WHO guidelines on physical activity and sedentary behaviour. URL: https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdfhttps://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf
Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66. DOI: 10.1016/j.jhep.2012.02.023.
DOI: 10.1016/j.jhep.2012.02.023
Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В., Ершова Е.В. и др. Ожирение: клинические рекомендации. М.; 2020.
Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–52. DOI: 10.1016/j.jhep.2016.08.023.
DOI: 10.1016/j.jhep.2016.08.023
Katsagoni C.N., Georgoulis M., Papatheodoridis G.V., Panagiotakos D.B., Kontogianni M.D. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119–32. DOI: 10.1016/j.metabol.2016.12.006.
DOI: 10.1016/j.metabol.2016.12.006
Golabi P., Locklear C.T., Austin P., Afdhal S., Byrns M., Gerber L., et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol. 2016;22(27):6318–27. DOI: 10.3748/wjg.v22.i27.6318.
DOI: 10.3748/wjg.v22.i27.6318
Smart N.A., King N., McFarlane J.R., Graham P.L., Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br J Sports Med. 2018;52(13):834–43. DOI: 10.1136/bjsports-2016-096197.
DOI: 10.1136/bjsports-2016-096197
Cheng S., Ge J., Zhao C., Le S., Yang Y., Ke D., et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. DOI: 10.1038/s41598-017-16159-x.
DOI: 10.1038/s41598-017-16159-x
Hallsworth K., Thoma C., Hollingsworth K.G., Cassidy S., Anstee Q.M., Day C.P., et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomized controlled trial. Clin Sci (Lond). 2015;129(12):1097–105. DOI: 10.1042/CS20150308.
DOI: 10.1042/CS20150308
Rector R.S., Thyfault J.P., Morris R.T., Laye M.J., Borengasser S.J., Booth F.W., et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol. 2008;294(3):G619–26. DOI: 10.1152/ajpgi.00428.2007.
DOI: 10.1152/ajpgi.00428.2007
Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323.
DOI: 10.1097/HEP.0000000000000323
Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323.
DOI: 10.1097/HEP.0000000000000323
Zelber-Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936–49. DOI: 10.1111/liv.13435.
DOI: 10.1111/liv.13435
Haigh L., Kirk C., El Gendy K., Gallacher J., Errington L., Mathers J.C., et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–31. DOI: 10.1016/j.clnu.2022.06.037.
DOI: 10.1016/j.clnu.2022.06.037
Younossi Z.M., Corey K.E., Lim J.K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2021;160(3):912–8. DOI: 10.1053/j.gastro.2020.11.051.
DOI: 10.1053/j.gastro.2020.11.051
Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012;142(6):1026–32. DOI: 10.3945/jn.111.157263.
DOI: 10.3945/jn.111.157263
Aller R., Izaola O., de la Fuente B., De Luis Román D.A. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr Hosp. 2015;32(6):2518–24. DOI: 10.3305/nh.2015.32.6.10074.
DOI: 10.3305/nh.2015.32.6.10074
Abenavoli L., Greco M., Nazionale I., Peta V., Milic N., Accattato F., et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519–27. DOI: 10.1586/17474124.2015.1004312.
DOI: 10.1586/17474124.2015.1004312
Ryan M.C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43. DOI: 10.1016/j.jhep.2013.02.012.
DOI: 10.1016/j.jhep.2013.02.012
Trovato F.M., Martines G.F., Brischetto D., Trovato G., Catalano D. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease. World J Hepatol. 2016;8(33):1459–65. DOI: 10.4254/wjh.v8.i33.1459.
DOI: 10.4254/wjh.v8.i33.1459
Lee D., Chiavaroli L., Ayoub-Charette S., Khan T.A., Zurbau A., Au-Yeung F., et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. DOI: 10.3390/nu14142846.
DOI: 10.3390/nu14142846
Liu W., Zhai D., Zhang T., Mudoti N.G., Chang Q., Liu Y., et al. Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. Food Funct. 2023;14(12):5551–61. DOI: 10.1039/d3fo00882g.
DOI: 10.1039/d3fo00882g
Zhang X.L., Wang T.Y., Targher G., Byrne C.D., Zheng M.H. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J. 2022;46(3):391–401. DOI: 10.4093/dmj.2022.0048.
DOI: 10.4093/dmj.2022.0048
Wong V.W., Wong G.L., Chan R.S., Shu S.S., Cheung B.H., Li L.S., et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349–56. DOI: 10.1016/j.jhep.2018.08.011.
DOI: 10.1016/j.jhep.2018.08.011
Long M.T., Noureddin M., Lim J.K. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review. Gastroenterology. 2022;163(3):764–74.e1. DOI: 10.1053/j.gastro.2022.06.023.
DOI: 10.1053/j.gastro.2022.06.023
Francque S.M., Marchesini G., Kautz A., Walmsley M., Dorner R., Lazarus J.V., et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021;3(5):100322. DOI: 10.1016/j.jhepr.2021.100322.
DOI: 10.1016/j.jhepr.2021.100322
Jarvis H., O’Keefe H., Craig D., Stow D., Hanratty B., Anstee Q.M. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 2022;12(1):e049767. DOI: 10.1136/bmjopen-2021-049767.
DOI: 10.1136/bmjopen-2021-049767
Di Ciaula A., Bonfrate L., Krawczyk M., Frühbeck G., Portincasa P. Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci. 2022;23(5):2636. DOI: 10.3390/ijms23052636.
DOI: 10.3390/ijms23052636
Long M.T., Massaro J.M., Hoffmann U., Benjamin E.J., Naimi T.S. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–41.e5. DOI: 10.1016/j.cgh.2019.11.022.
DOI: 10.1016/j.cgh.2019.11.022
El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(9):2215. DOI: 10.3390/ijms20092215.
DOI: 10.3390/ijms20092215
Lizardi-Cervera J., Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8(Suppl. 1):S40–3. DOI: 10.1016/S1665-2681(19)31825-3.
DOI: 10.1016/S1665-2681(19)31825-3
Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. DOI: 10.1053/j.gastro.2015.04.043.
DOI: 10.1053/j.gastro.2015.04.043
Kwo P.Y., Cohen S.M., Lim J.K. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. DOI: 10.1038/ajg.2016.517.
DOI: 10.1038/ajg.2016.517
Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ. 2004;328(7446):983. DOI: 10.1136/bmj.38050.593634.63.
DOI: 10.1136/bmj.38050.593634.63
Lee T.H., Kim W.R., Benson J.T., Therneau T.M., Melton L.J. 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47(3):880–7. DOI: 10.1002/hep.22090.
DOI: 10.1002/hep.22090
Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477–85.e11. DOI: 10.1053/j.gastro.2008.10.052.
DOI: 10.1053/j.gastro.2008.10.052
Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43(5):1145–51. DOI: 10.1002/hep.21171.
DOI: 10.1002/hep.21171
Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., Chase T.J.G., et al. Lifestyle modifications for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;6(6):CD013156. DOI: 10.1002/14651858.CD013156.pub2.
DOI: 10.1002/14651858.CD013156.pub2
Komolafe O., Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., et al. Nutritional supplementation for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;7(7):CD013157. DOI: 10.1002/14651858.CD013157.pub2.
DOI: 10.1002/14651858.CD013157.pub2
Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46. DOI: 10.1016/j.jhep.2017.05.016.
DOI: 10.1016/j.jhep.2017.05.016
Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. DOI: 10.1002/14651858.CD003619.pub3.
DOI: 10.1002/14651858.CD003619.pub3
Xiang Z., Chen Y.P., Ma K.F., Ye Y.F., Zheng L., Yang Y.D., et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: A systematic review. BMC Gastroenterol. 2013;13:140. DOI: 10.1186/1471-230X-13-140.
DOI: 10.1186/1471-230X-13-140
Simental-Mendía M., Sánchez-García A., Simental-Mendía L.E. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol. 2020;86(8):1476–88. DOI: 10.1111/bcp.14311.
DOI: 10.1111/bcp.14311
Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology. 1996;23(6):1464–7. DOI: 10.1002/hep.510230624.
DOI: 10.1002/hep.510230624
Ozel Coskun B.D., Yucesoy M., Gursoy S., Baskol M., Yurci A., Yagbasan A., et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(2):142–9. DOI: 10.1097/MEG.0000000000000264.
DOI: 10.1097/MEG.0000000000000264
Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1011–9. DOI: 10.1016/j.jhep.2010.08.030.
DOI: 10.1016/j.jhep.2010.08.030
Павлов Ч.С., Варганова Д.Л., Семенистая М.Ч., Кузнецова Е.А., Усанова А.А., Свистунов А.А. Урсодезоксихолевая кислота: эффективность и безопасность в лечении неалкогольной жировой болезни печени (метаанализ). Вестник Российской академии медицинских наук. 2018;73(5):294–305. DOI: 10.15690/vramn975.
DOI: 10.15690/vramn975
Zhang W., Tang Y., Huang J., Hu H. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29(4):696–705. DOI: 10.6133/apjcn.202012_29(4).0004.
DOI: 10.6133/apjcn.202012_29(4).0004
Lin X., Mai M., He T., Huang H., Zhang P., Xia E., et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–45. DOI: 10.1080/17474124.2022.2083605.
DOI: 10.1080/17474124.2022.2083605
Nadinskaia M., Maevskaya M., Ivashkin V., Kodzoeva K., Pirogova I., Chesnokov E., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–75. DOI: 10.3748/wjg.v27.i10.959.
DOI: 10.3748/wjg.v27.i10.959
Byrnes K., Blessinger S., Bailey N.T., Scaife R., Liu G., Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12(1):33–49. DOI: 10.1016/j.apsb.2021.07.021.
DOI: 10.1016/j.apsb.2021.07.021
Decuypere J.P., Parys J.B., Bultynck G. Regulation of the autophagic bcl-2/beclin 1 interaction. Cells. 2012;1(3):284–312. DOI: 10.3390/cells1030284.
DOI: 10.3390/cells1030284
Carino A., Biagioli M., Marchianò S., Fiorucci C., Zampella A., Monti M.C., et al. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(10):1422–37. DOI: 10.1016/j.bbalip.2019.07.006.
DOI: 10.1016/j.bbalip.2019.07.006
Marchianò S., Biagioli M., Roselli R., Zampella A., Di Giorgio C., Bordoni M., et al. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(11):159218. DOI: 10.1016/j.bbalip.2022.159218.
DOI: 10.1016/j.bbalip.2022.159218
Karedath J., Javed H., Ahsan Talpur F., Lal B., Kumari A., Kivan H., et al. Effect of vitamin E on clinical outcomes in patients with non-alcoholic fatty liver disease: A meta-analysis. Cureus. 2022;14(12):e32764. DOI: 10.7759/cureus.32764.
DOI: 10.7759/cureus.32764
Bril F., Biernacki D.M., Kalavalapalli S., Lomonaco R., Subbarayan S.K., Lai J., et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2019;42(8):1481–8. DOI: 10.2337/dc19-0167.
DOI: 10.2337/dc19-0167
Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: A meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34.
Mazhar I.J., Yasir M., Sarfraz S., Shlaghya G., Narayana S.H., Mushtaq U., et al. Vitamin E and pioglitazone: A comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease. Cureus. 2023;15(8):e43635. DOI: 10.7759/cureus.43635.
DOI: 10.7759/cureus.43635
Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1002/hep.30368.
DOI: 10.1002/hep.30368
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004.
DOI: 10.1016/j.jhep.2015.11.004
Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367.
DOI: 10.1002/hep.29367
Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. DOI: 10.1056/NEJMoa0907929.
DOI: 10.1056/NEJMoa0907929
Ando Y., Jou J.H. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021;17(1):23–8. DOI: 10.1002/cld.1045.
DOI: 10.1002/cld.1045
Bjelakovic G., Nikolova D., Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: Do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. DOI: 10.1371/journal.pone.0074558.
DOI: 10.1371/journal.pone.0074558
Miller E.R. 3rd, Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. DOI: 10.7326/0003-4819-142-1-200501040-00110.
DOI: 10.7326/0003-4819-142-1-200501040-00110
Curtis A.J., Bullen M., Piccenna L., McNeil J.J. Vitamin E supplementation and mortality in healthy people: A meta-analysis of randomised controlled trials. Cardiovasc Drugs Ther. 2014;28(6):563–73. DOI: 10.1007/s10557-014-6560-7.
DOI: 10.1007/s10557-014-6560-7
Vivarelli F., Canistro D., Cirillo S., Papi A., Spisni E., Vornoli A., et al. Co-carcinogenic effects of vitamin E in prostate. Sci Rep. 2019;9(1):11636. DOI: 10.1038/s41598-019-48213-1.
DOI: 10.1038/s41598-019-48213-1
Podszun M., Frank J. Vitamin E-drug interactions: Molecular basis and clinical relevance. Nutr Res Rev. 2014;27(2):215–31. DOI: 10.1017/S0954422414000146.
DOI: 10.1017/S0954422414000146
Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46.
DOI: 10.4254/wjh.v12.i2.46
Райхельсон К.Л., Кондрашина Э.А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134–42. DOI: 10.26442/00403660.2019.02.000130.
DOI: 10.26442/00403660.2019.02.000130
Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3–10.
Shankar R., Virukalpattigopalratnam M.P., Singh T. Heptral® (Ademetionine) in intrahepatic cholestasis due to chronic non-alcoholic liver disease: Subgroup analysis of results of a multicentre observational study in India. J Clin Exp Hepatol. 2014;4(Suppl. 2):S33. DOI: 10.1016/j.jceh.2014.02.071.
DOI: 10.1016/j.jceh.2014.02.071
Li H., Liu N.N., Peng Z.G. Effect of bicyclol on blood biomarkers of NAFLD: A systematic review and meta-analysis. BMJ Open. 2020;10(12):e039700. DOI: 10.1136/bmjopen-2020-039700.
DOI: 10.1136/bmjopen-2020-039700
Маевская М.В., Луньков В.Д., Гейвандова Н.И., Пальгова Л.К., Пирогова И.Ю., Прашнова М.К. и др. Бициклол в лечении пациентов с хроническими диффузными заболеваниями печени. Медицинский совет. 2020;(15):78–89. DOI: 10.21518/2079-701X-2020-15-78-89.
DOI: 10.21518/2079-701X-2020-15-78-89
Pan S.Y., Dong H., Yu Z.L., Zhao X.Y., Xiang C.J., Wang H., et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 2007;59(12):1657–62. DOI: 10.1211/jpp.59.12.0007.
DOI: 10.1211/jpp.59.12.0007
Pan S.Y., Yu Z.L., Dong H., Xiang C.J., Fong W.F., Ko K.M. Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Evid Based Complement Alternat Med. 2011;2011:729412. DOI: 10.1093/ecam/nep070.
DOI: 10.1093/ecam/nep070
Zhao W., Yan Y., Xiao Z., Wang M., Xu M., Wang Z., et al. Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways. Biomed Pharmacother. 2021;141:111874. DOI: 10.1016/j.biopha.2021.111874.
DOI: 10.1016/j.biopha.2021.111874
Пирогова И.Ю., Яковлева С.В., Неуймина Т.В., Синицын С.П., Чулков В.С., Шамаева Т.Н. Эффективность и безопасность Бициклола при неалкогольной жировой болезни печени: результаты когортного исследования. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(4):66–75. DOI: 10.22416/1382-4376-2018-28-4-66-75.
DOI: 10.22416/1382-4376-2018-28-4-66-75
Оковитый С.В., Приходько В.А., Безбородкина Н.Н., Кудрявцев Б.Н. Гепатопротекторы: руководство для врачей. 2-е изд. М.: ГЭОТАР-Медиа; 2022. DOI: 10.33029/9704-6689-6-LIV-1-240.
DOI: 10.33029/9704-6689-6-LIV-1-240
Семисерин В.А., Каракозов А.Г., Малькута М.А., Золотарева Л.А., Левченко О.Б., Калягин И.Е. и др. Оценка эффективности гепатопротективной монотерапии неалкогольной жировой болезни печени в стадии стеатогепатита препаратом на основе янтарной кислоты и метионина. Терапевтический архив. 2016;88(2):58–63. DOI: 10.17116/terarkh201688258-63.
DOI: 10.17116/terarkh201688258-63
Стельмах В.В., Козлов В.К., Баранов В.Л., Латария Э.Л., Некрасова А.С. Энерготропная патогенетически ориентированная терапия сукцинатсодержащими препаратами при неалкогольной жировой болезни печени: перспективы клинического применения. Медицинский алфавит. 2013;1(2):38–44.
Дударенко С.В., Коваленко А.Л., Прокопенко С.М., Белогурова Е.В. Применение ремаксола в терапии метаболического синдрома у пациентов с неалкогольным стеатогепатитом и сахарным диабетом 2 типа. Экспериментальная и клиническая гастроэнтерология. 2016;6:89–94.
Шиповская А.А., Дуданова О.П. Внутрипеченочный холестаз при неалкогольной жировой болезни печени. Терапевтический архив. 2018;90(2):69–74. DOI: 10.26442/terarkh201890269-74.
DOI: 10.26442/terarkh201890269-74
Pennisi G., Pipitone R.M., Grimaudo S., Spatola F., Di Martino V., Cammà C., et al. A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2021;53(Suppl. 1):S27. DOI: 10.1016/j.dld.2020.12.069.
DOI: 10.1016/j.dld.2020.12.069
Широкова Е.Н. Внутрипеченочный холестаз при неалкогольной жировой болезни печени: патогенез и роль адеметионина в терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(2):79–86. DOI: 10.22416/1382-4376-2023-33-2-79-86.
DOI: 10.22416/1382-4376-2023-33-2-79-86
Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097–109. DOI: 10.1016/j.jhep.2012.04.041.
DOI: 10.1016/j.jhep.2012.04.041
Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301–13. DOI: 10.1016/j.jceh.2018.05.004.
DOI: 10.1016/j.jceh.2018.05.004
Ермолова Т.В., Ермолов С.Ю., Сологуб Т.В., Карев В.Е., Добкес А.Л., Апресян А.Г. Нарушения портопеченочной гемодинамики при хронических заболеваниях печени на начальных стадиях фиброза и их коррекция. Фарматека. 2016;(15):58–66.
Зыкина Е.Ю., Симонова Ж.Г. Гипераммониемия у пациентов со стабильной стенокардией и неалкогольной жировой болезнью печени на стадии стеатоза. Экспериментальная и клиническая гастроэнтерология. 2023;8:57–65. DOI: 10.31146/1682-8658-ecg-216-8-57-65.
DOI: 10.31146/1682-8658-ecg-216-8-57-65
Гаранина Е.В. Влияние курсового приема L-орнитинL-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезнью печени), имеющих гипераммониемию. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):31–6. DOI: 10.22416/1382-4376-2021-31-4-31-36.
DOI: 10.22416/1382-4376-2021-31-4-31-36
Kaiser S., Gerok W., Häussinger D. Ammonia and glutamine metabolism in human liver slices: New aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest. 1988;18(5):535–42. DOI: 10.1111/j.1365-2362.1988.tb01053.x.
DOI: 10.1111/j.1365-2362.1988.tb01053.x
De Chiara F., Heebøll S., Marrone G., Montoliu C., Hamilton-Dutoit S., Ferrandez A., et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):905–15. DOI: 10.1016/j.jhep.2018.06.023.
DOI: 10.1016/j.jhep.2018.06.023
Алексеенко С.А., Агеева Е.А., Полковникова О.П. Современные подходы к диагностике и лечению гипераммониемии у пациентов с хроническими заболеваниями печени на доцирротической стадии. РМЖ. Медицинское обозрение. 2018;2(7-1):19–23.
Tian L.Y., Lu L.G., Tang C.W., Xie Y., Luo H.S., Tan S.Y., et al. Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: A multiple-dose parallel controlled clinical trial. Zhonghua Gan Zang Bing Za Zhi. 2013;21(7):528–32. (In Chinese). DOI: 10.3760/cma.j.issn.1007-3418.2013.07.013.
DOI: 10.3760/cma.j.issn.1007-3418.2013.07.013
Pichon C., Nachit M., Gillard J., Vande Velde G., Lanthier N., Leclercq I.A. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. Front Nutr. 2022;9:1051157. DOI: 10.3389/fnut.2022.1051157.
DOI: 10.3389/fnut.2022.1051157
Приходько В.А., Сысоев Ю.И., Поверяева М.А., Бунят А.В., Карев В.Е., Ивкин Д.Ю. и др. Влияние эмпаглифлозина и L-орнитина L-аспартата на поведенческокогнитивные функции и физическую работоспособность при экспериментальном стеатогепатите. Вестник РГМУ. 2020;3:53–62. DOI: 10.24075/brsmu.2020.034.
DOI: 10.24075/brsmu.2020.034
Оковитый С.В., Райхельсон К.Л., Приходько В.А. Комбинированная гепатопротекторная фармакотерапия заболеваний печени. Экспериментальная и клиническая гастроэнтерология. 2022;7:5–20. DOI: 10.31146/1682-8658-ecg-203-7-5-20.
DOI: 10.31146/1682-8658-ecg-203-7-5-20
Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4(12):1537–43. DOI: 10.1016/j.cgh.2006.09.025.
DOI: 10.1016/j.cgh.2006.09.025
Pietu F., Guillaud O., Walter T., Vallin M., Hervieu V., Scoazec J.Y., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin Res Hepatol Gastroenterol. 2012;36(2):146–55. DOI: 10.1016/j.clinre.2011.10.011.
DOI: 10.1016/j.clinre.2011.10.011
Balmer M.L., Siegrist K., Zimmermann A., Dufour J.F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29(8):1184–8. DOI: 10.1111/j.1478-3231.2009.02037.x.
DOI: 10.1111/j.1478-3231.2009.02037.x
Thomsen M.N., Skytte M.J., Samkani A., Carl M.H., Weber P., Astrup A., et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: A randomised controlled trial. Diabetologia. 2022;65(3):506–17. DOI: 10.1007/s00125-021-05628-8.
DOI: 10.1007/s00125-021-05628-8
Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5. DOI: 10.1053/j.gastro.2015.04.005.
DOI: 10.1053/j.gastro.2015.04.005
Wong C., Lee M.H., Yaow C.Y.L., Chin Y.H., Goh X.L., Ng C.H., et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis. Front Endocrinol (Lausanne). 2021;12:609110. DOI: 10.3389/fendo.2021.609110.
DOI: 10.3389/fendo.2021.609110
Fan S., Shi X., Yao J., Zhong M., Feng P. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig. 2020;112(8):627–35. DOI: 10.17235/reed.2020.6392/2019.
DOI: 10.17235/reed.2020.6392/2019
Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395.
DOI: 10.1056/NEJMoa2028395
Zhu K., Kakkar R., Chahal D., Yoshida E.M., Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol. 2023;29(37):5327–38. DOI: 10.3748/wjg.v29.i37.5327.
DOI: 10.3748/wjg.v29.i37.5327
Bandyopadhyay S., Das S., Samajdar S.S., Joshi S.R. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(10):102849. DOI: 10.1016/j.dsx.2023.102849.
DOI: 10.1016/j.dsx.2023.102849
Gu Y., Sun L., Zhang W., Kong T., Zhou R., He Y., et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792. DOI: 10.3389/fphar.2023.1102792.
DOI: 10.3389/fphar.2023.1102792
Parab P., Chaudhary P., Mukhtar S., Moradi A., Kodali A., Okoye C., et al. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: A systematic review. Cureus. 2023;15(9):e45487. DOI: 10.7759/cureus.45487.
DOI: 10.7759/cureus.45487
Banerjee M., Pal R., Mukhopadhyay S., Nair K. GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023;108(7):1806–12. DOI: 10.1210/clinem/dgad076.
DOI: 10.1210/clinem/dgad076
Gomes D.A., Presume J., de Araújo Gonçalves P., Almeida M.S., Mendes M., Ferreira J. Association between the magnitude of glycemic control and body weight loss with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: A systematic review and meta-analyses of randomized diabetes cardiovascular outcomes trials. Cardiovasc Drugs Ther. 2024. DOI: 10.1007/s10557-024-07547-3.
DOI: 10.1007/s10557-024-07547-3
Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774.
DOI: 10.7326/M15-1774
Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607.
DOI: 10.1001/jamainternmed.2016.9607
Zhao Y., Zhao W., Wang H., Zhao Y., Bu H., Takahashi H. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. Medicine (Baltimore). 2022;101(46):e31508. DOI: 10.1097/MD.0000000000031508.
DOI: 10.1097/MD.0000000000031508
Ndakotsu A., Vivekanandan G. The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: A systematic review. Cureus. 2022;14(5):e25380. DOI: 10.7759/cureus.25380.
DOI: 10.7759/cureus.25380
Budd J., Cusi K. Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020;20(11):59. DOI: 10.1007/s11892-020-01349-1.
DOI: 10.1007/s11892-020-01349-1
Государственный реестр лекарственных средств. Пиоглар. Номер ЛС-001671, дата регистрации 16.07.2011. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220
Государственный реестр лекарственных средств. Пиоглар. Номер ЛС-001671, дата регистрации 16.07.2011. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220
Gautam A., Agrawal P.K., Doneria J., Nigam A. Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease. J Assoc Physicians India. 2018;66(8):62–6.
Wei Q., Xu X., Guo L., Li J., Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:635556. DOI: 10.3389/fendo.2021.635556.
DOI: 10.3389/fendo.2021.635556
Приходько В.А., Оковитый С.В., Куликов А.Н. Глифлозины при неалкогольной жировой болезни печени: перспективы применения за границами диабета, кардио- и нефропротекции. Терапия. 2023;9(7):130–41. DOI: 10.18565/therapy.2023.7.130-141.
DOI: 10.18565/therapy.2023.7.130-141
Mo M., Huang Z., Liang Y., Liao Y., Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig Liver Dis. 2022;54(4):461–8. DOI: 10.1016/j.dld.2021.08.017.
DOI: 10.1016/j.dld.2021.08.017
Jin Z., Yuan Y., Zheng C., Liu S., Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37(8):108558. DOI: 10.1016/j.jdiacomp.2023.108558.
DOI: 10.1016/j.jdiacomp.2023.108558
Ong Lopez A.M.C., Pajimna J.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. DOI: 10.1038/s41598-024-52603-5.
DOI: 10.1038/s41598-024-52603-5
Sánchez-García A., Sahebkar A., Simental-Mendía M., Simental-Mendía L.E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018;135:144–9. DOI: 10.1016/j.phrs.2018.08.008.
DOI: 10.1016/j.phrs.2018.08.008
Elhini S.H., Wahsh E.A., Elberry A.A., El Ameen N.F., Abdelfadil Saedii A., Refaie S.M., et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel). 2022;15(12):1516. DOI: 10.3390/ph15121516.
DOI: 10.3390/ph15121516
Houttu V., Csader S., Nieuwdorp M., Holleboom A.G., Schwab U. Dietary interventions in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Nutr. 2021;8:716783. DOI: 10.3389/fnut.2021.716783.
DOI: 10.3389/fnut.2021.716783
Koutoukidis D.A., Astbury N.M., Tudor K.E., Morris E., Henry J.A., Noreik M., et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: A systematic review and meta-analysis. JAMA Intern Med. 2019;179(9):1262–71. DOI: 10.1001/jamainternmed.2019.2248.
DOI: 10.1001/jamainternmed.2019.2248
Ezpeleta M., Gabel K., Cienfuegos S., Kalam F., Lin S., Pavlou V., et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab. 2023;35(1):56–70.e3. DOI: 10.1016/j.cmet.2022.12.001.
DOI: 10.1016/j.cmet.2022.12.001
Haufe S., Engeli S., Kast P., Böhnke J., Utz W., Haas V., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504–14. DOI: 10.1002/hep.24242.
DOI: 10.1002/hep.24242
Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186–90. DOI: 10.1016/j.clnu.2013.11.003.
DOI: 10.1016/j.clnu.2013.11.003
Lemstra M., Bird Y., Nwankwo C., Rogers M., Moraros J. Weight loss intervention adherence and factors promoting adherence: A meta-analysis. Patient Prefer Adherence. 2016;10:1547–59. DOI: 10.2147/PPA.S103649.
DOI: 10.2147/PPA.S103649
Scragg J., Hallsworth K., Taylor G., Cassidy S., Haigh L., Boyle M., et al. Factors associated with engagement and adherence to a low-energy diet to promote 10 [%] weight loss in patients with clinically significant non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2021;8(1):e000678. DOI: 10.1136/bmjgast-2021-000678.
DOI: 10.1136/bmjgast-2021-000678
Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-X.
DOI: 10.1016/S0140-6736(15)00803-X
Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. DOI: 10.1136/bmj.d7771.
DOI: 10.1136/bmj.d7771
Stokes C.S., Gluud L.L., Casper M., Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: A meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12(7):1090–100.e2. DOI: 10.1016/j.cgh.2013.11.031.
DOI: 10.1016/j.cgh.2013.11.031
Fearon N.M., Kearns E.C., Kennedy C.A., Conneely J.B., Heneghan H.M. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: A meta-analysis of randomized control trials. Surg Obes Relat Dis. 2022;18(1):77–84. DOI: 10.1016/j.soard.2021.10.004.
DOI: 10.1016/j.soard.2021.10.004
Mulliri A., Menahem B., Alves A., Dupont B. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: A meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39. DOI: 10.1007/s00535-022-01886-4.
DOI: 10.1007/s00535-022-01886-4
Machado F.H.F., Castro Filho H.F., Babadopulos R.F.A.L., Rocha H.A.L., Rocha J.L.C., Moraes Filho M.O. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019;34(1):e20190010000009. DOI: 10.1590/s0102-865020190010000009.
DOI: 10.1590/s0102-865020190010000009
Johansson K., Sundström J., Marcus C., Hemmingsson E., Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond). 2014;38(2):279–84. DOI: 10.1038/ijo.2013.83.
DOI: 10.1038/ijo.2013.83
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146–81. DOI: 10.1016/j.jhep.2016.03.005.
DOI: 10.1016/j.jhep.2016.03.005
Uy M.C., Talingdan-Te M.C., Espinosa W.Z., Daez M.L., Ong J.P. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: A meta-analysis. Obes Surg. 2008;18(12):1532–8. DOI: 10.1007/s11695-008-9587-7.
DOI: 10.1007/s11695-008-9587-7
Dongiovanni P., Petta S., Mannisto V., Mancina R.M., Pipitone R., Karja V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12. DOI: 10.1016/j.jhep.2015.05.006.
DOI: 10.1016/j.jhep.2015.05.006
Zhou H., Toshiyoshi M., Zhao W., Zhao Y., Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. DOI: 10.1097/MD.0000000000033981.
DOI: 10.1097/MD.0000000000033981
Pastori D., Sciacqua A., Marcucci R., Del Ben M., Baratta F., Violi F., et al. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Intern Emerg Med. 2021;16(8):2063–8. DOI: 10.1007/s11739-021-02682-3.
DOI: 10.1007/s11739-021-02682-3
Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455.
DOI: 10.1093/eurheartj/ehz455
Pastori D., Pani A., Di Rocco A., Menichelli D., Gazzaniga G., Farcomeni A., et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–51. DOI: 10.1111/bcp.14943.
DOI: 10.1111/bcp.14943
Abdallah M., Brown L., Provenza J., Tariq R., Gowda S., Singal A.K. Safety and efficacy of dyslipidemia treatment in NAFLD patients: A meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738. DOI: 10.1016/j.aohep.2022.100738.
DOI: 10.1016/j.aohep.2022.100738
Athyros V.G., Boutari C., Stavropoulos K., Anagnostis P., Imprialos K.P., Doumas M., et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol. 2018;16(3):246–53. DOI: 10.2174/1570161115666170621082910.
DOI: 10.2174/1570161115666170621082910
Torres-Peña J.D., Martín-Piedra L., Fuentes-Jiménez F. Statins in non-alcoholic steatohepatitis. Front Cardiovasc Med. 2021;8:777131. DOI: 10.3389/fcvm.2021.777131.
DOI: 10.3389/fcvm.2021.777131
Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58.
DOI: 10.1038/clpt.2011.58
Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и (или) желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;86(12):48–52. DOI: 10.17116/terarkh2014861248-52.
DOI: 10.17116/terarkh2014861248-52
Nadinskaya M., Martsevich S., Kutishenko N., Balashov I., Lerman O. P0624 Ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with high risk of cardiovascular events and nonalcoholic fatty liver disease: The RACURS study (post-hoc analysis). United European Gastroenterol J. 2015;3(Suppl. 5):P0624. DOI: 10.1177/2050640615601623.
DOI: 10.1177/2050640615601623
Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: A prospective clinical trial. Rev Clin Esp. 2004;204(12):632–5. (In Spanish). DOI: 10.1016/s0014-2565(04)71566-0.
DOI: 10.1016/s0014-2565(04)71566-0
Seo S.H., Lee D.H., Lee Y.S., Cho K.J., Park H.J., Lee H.W., et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterol Rep (Oxf). 2022;10:goac037. DOI: 10.1093/gastro/goac037.
DOI: 10.1093/gastro/goac037
Nakade Y., Murotani K., Inoue T., Kobayashi Y., Yamamoto T., Ishii N., et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47(13):1417–28. DOI: 10.1111/hepr.12887.
DOI: 10.1111/hepr.12887
Lee H.Y., Jun D.W., Kim H.J., Oh H., Saeed W.K., Ahn H., et al. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med. 2019;34(2):296–304. DOI: 10.3904/kjim.2017.194.
DOI: 10.3904/kjim.2017.194
Cho Y., Rhee H., Kim Y.E., Lee M., Lee B.W., Kang E.S., et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93. DOI: 10.1186/s12916-022-02288-2.
DOI: 10.1186/s12916-022-02288-2
Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the Welcome* study. Hepatology. 2014;60(4):1211–21. DOI: 10.1002/hep.27289.
DOI: 10.1002/hep.27289
Maciejewska-Markiewicz D., Stachowska E., Hawryłkowicz V., Stachowska L., Prowans P. The role of resolvins, protectins and marensins in non-alcoholic fatty liver disease (NAFLD). Biomolecules. 2021;11(7):937. DOI: 10.3390/biom11070937.
DOI: 10.3390/biom11070937
Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792.
DOI: 10.1056/NEJMoa1812792
Sanyal A.J., Abdelmalek M.F., Suzuki A., Cummings O.W., Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–84.e1. DOI: 10.1053/j.gastro.2014.04.046.
DOI: 10.1053/j.gastro.2014.04.046
Lee C.H., Fu Y., Yang S.J., Chi C.C. Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: A systematic review and meta-analysis. Nutrients. 2020;12(9):2769. DOI: 10.3390/nu12092769.
DOI: 10.3390/nu12092769
Musazadeh V., Karimi A., Malekahmadi M., Ahrabi S.S., Dehghan P. Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2023;50(5):327–34. DOI: 10.1111/1440-1681.13750.
DOI: 10.1111/1440-1681.13750
Yan J.H., Guan B.J., Gao H.Y., Peng X.E. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(37):e12271. DOI: 10.1097/MD.0000000000012271.
DOI: 10.1097/MD.0000000000012271
Hilleman D.E., Wiggins B.S., Bottorff M.B. Critical differences between dietary supplement and prescription omega-3 fatty acids: A narrative review. Adv Ther. 2020;37(2):656–70. DOI: 10.1007/s12325-019-01211-1.
DOI: 10.1007/s12325-019-01211-1
Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5. DOI: 10.1016/j.dld.2007.10.002.
DOI: 10.1016/j.dld.2007.10.002
Mahmoudi A., Moallem S.A., Johnston T.P., Sahebkar A. Liver protective effect of fenofibrate in NASH/NAFLD animal models. PPAR Res. 2022;2022:5805398. DOI: 10.1155/2022/5805398.
DOI: 10.1155/2022/5805398
Lawitz E.J., Bhandari B.R., Ruane P.J., Kohli A., Harting E., Ding D., et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21(1):143–52.e3. DOI: 10.1016/j.cgh.2021.12.044.
DOI: 10.1016/j.cgh.2021.12.044
Maev I.V., Samsonov A.A., Palgova L.K., Pavlov C.S., Shirokova E.N., Vovk E.I., et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: Real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368. DOI: 10.1136/bmjgast-2019-000368.
DOI: 10.1136/bmjgast-2019-000368
Dajani A.I, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8(21):5235–49. DOI: 10.12998/wjcc.v8.i21.5235.
DOI: 10.12998/wjcc.v8.i21.5235
Kuche K., Bhargavi N., Dora C.P., Jain S. Drug-phospholipid complex — a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20(2):43. DOI: 10.1208/s12249-018-1252-4.
DOI: 10.1208/s12249-018-1252-4
Оковитый С.В., Болотова В.Ц., Анисимова Н.А., Ивкин Д.Ю., Титович И.А., Сысоев Ю.И. и др. Перспективы применения растительных извлечений для коррекции нарушений жирового и углеводного обмена. Фармация. 2020;69(2):17–22. DOI: 10.29296/25419218-2020-02-03.
DOI: 10.29296/25419218-2020-02-03
Dimakopoulou A., Sfikas G., Athyros V. PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia. Hell J Atheroscler. 2018;9(2):12. DOI: 10.23803/HJA.V9I2.175.G150.
DOI: 10.23803/HJA.V9I2.175.G150
Rimbert A., Smati S., Dijk W., Le May C., Cariou B. Genetic inhibition of PCSK9 and liver function. JAMA Cardiol. 2021;6(3):353–4. DOI: 10.1001/jamacardio.2020.5341.
DOI: 10.1001/jamacardio.2020.5341
Jang H.R., Kang D., Sinn D.H., Gu S., Cho S.J., Lee J.E., et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: A cohort study. Sci Rep. 2018;8(1):4718. DOI: 10.1038/s41598-018-23014-0.
DOI: 10.1038/s41598-018-23014-0
Musso G., Gambino R., Tabibian J.H., Ekstedt M., Kechagias S., Hamaguchi M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. DOI: 10.1371/journal.pmed.1001680.
DOI: 10.1371/journal.pmed.1001680
Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Lippi G., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19(8):1564–70. DOI: 10.1681/ASN.2007101155.
DOI: 10.1681/ASN.2007101155
Heda R., Yazawa M., Shi M., Bhaskaran M., Aloor F.Z., Thuluvath P.J., et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 2021;27(17):1864–82. DOI: 10.3748/wjg.v27.i17.1864.
DOI: 10.3748/wjg.v27.i17.1864
Monteillet L., Gjorgjieva M., Silva M., Verzieux V., Imikirene L., Duchampt A., et al. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Mol Metab. 2018;16:100–15. DOI: 10.1016/j.molmet.2018.07.006.
DOI: 10.1016/j.molmet.2018.07.006
Shimano H., Sato R. SREBP-regulated lipid metabolism: Convergent physiology — divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–30. DOI: 10.1038/nrendo.2017.91.
DOI: 10.1038/nrendo.2017.91
Marcuccilli M., Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):562. DOI: 10.3390/ijms17040562.
DOI: 10.3390/ijms17040562
Kwon S.Y., Park J., Park S.H., Lee Y.B., Kim G., Hur K.Y., et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023;13(1):1796. DOI: 10.1038/s41598-023-27762-6.
DOI: 10.1038/s41598-023-27762-6
Zhang X., Wong G.L., Yip T.C., Tse Y.K., Liang L.Y., Hui V.W., et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469–82. DOI: 10.1002/hep.32294.
DOI: 10.1002/hep.32294
Hirata T., Tomita K., Kawai T., Yokoyama H., Shimada A., Kikuchi M., et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013:587140. DOI: 10.1155/2013/587140.
DOI: 10.1155/2013/587140
Georgescu E.F., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16(1):39–46.
Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15(8):942–54. DOI: 10.3748/wjg.15.942.
DOI: 10.3748/wjg.15.942
Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222–5. DOI: 10.1002/hep.20420.
DOI: 10.1002/hep.20420
Osterreicher C.H., Taura K., De Minicis S., Seki E., Penz-Osterreicher M., Kodama Y., et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929–38. DOI: 10.1002/hep.23104.
DOI: 10.1002/hep.23104
Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. DOI: 10.1210/endocr/bqab157.
DOI: 10.1210/endocr/bqab157
Toyama T., Neuen B.L., Jun M., Ohkuma T., Neal B., Jardine M.J., et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–50. DOI: 10.1111/dom.13648.
DOI: 10.1111/dom.13648
Sarafidis P., Ferro C.J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–30. DOI: 10.1093/ndt/gfy407.
DOI: 10.1093/ndt/gfy407
Musso G., Cassader M., Cohney S., De Michieli F., Pinach S., Saba F., et al. Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities. Diabetes Care. 2016;39(10):1830–45. DOI: 10.2337/dc15-1182.
DOI: 10.2337/dc15-1182
Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. DOI: 10.1056/NEJMoa2024816.
DOI: 10.1056/NEJMoa2024816
Herrington W.G., Staplin N., Wanner C., Green J.B., Hauske S.J., Emberson J.R., et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. DOI: 10.1056/NEJMoa2204233.
DOI: 10.1056/NEJMoa2204233
Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. DOI: 10.1136/bmj.m4573.
DOI: 10.1136/bmj.m4573
Greco E.V., Russo G., Giandalia A., Viazzi F., Pontremoli R., De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019;55(6):233. DOI: 10.3390/medicina55060233.
DOI: 10.3390/medicina55060233
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. DOI: 10.1056/NEJMoa1603827.
DOI: 10.1056/NEJMoa1603827
Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. DOI: 10.1056/NEJMoa1607141.
DOI: 10.1056/NEJMoa1607141
Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. DOI: 10.1016/S0140-6736(19)31149-3.
DOI: 10.1016/S0140-6736(19)31149-3
Zhang Y., Jiang L., Wang J., Wang T., Chien C., Huang W., et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232. DOI: 10.1186/s12933-022-01676-5.
DOI: 10.1186/s12933-022-01676-5
Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.
Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80. DOI: 10.1002/hep.1840110114.
DOI: 10.1002/hep.1840110114
Ajmera V., Belt P., Wilson L.A., Gill R.M., Loomba R., Kleiner D.E., et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511–20.e5. DOI: 10.1016/j.cgh.2018.01.026.
DOI: 10.1016/j.cgh.2018.01.026
Kimura T., Tanaka N., Fujimori N., Sugiura A., Yamazaki T., Joshita S., et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24(13):1440–50. DOI: 10.3748/wjg.v24.i13.1440.
DOI: 10.3748/wjg.v24.i13.1440
Younossi Z.M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625–33.e1. DOI: 10.1016/j.cgh.2018.11.033.
DOI: 10.1016/j.cgh.2018.11.033
Ekstedt M., Franzén L.E., Holmqvist M., Bendtsen P., Mathiesen U.L., Bodemar G., et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44(3):366–74. DOI: 10.1080/00365520802555991.
DOI: 10.1080/00365520802555991
Sookoian S., Castaño G.O., Pirola C.J. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: A meta-analysis of 43,175 individuals. Gut. 2014;63(3):530–2. DOI: 10.1136/gutjnl-2013-305718.
DOI: 10.1136/gutjnl-2013-305718
Cao G., Yi T., Liu Q., Wang M., Tang S. Alcohol consumption and risk of fatty liver disease: A meta-analysis. PeerJ. 2016;4:e2633. DOI: 10.7717/peerj.2633.
DOI: 10.7717/peerj.2633
Chang Y., Cho Y.K., Kim Y., Sung E., Ahn J., Jung H.S., et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study. Hepatology. 2019;69(1):64–75. DOI: 10.1002/hep.30170.
DOI: 10.1002/hep.30170
Blomdahl J., Nasr P., Ekstedt M., Kechagias S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun. 2023;7(1):e0003. DOI: 10.1097/HC9.0000000000000003.
DOI: 10.1097/HC9.0000000000000003
Ивашкин В.Т., Жаркова М.С., Корочанская Н.В., Хлынов И.Б., Успенский Ю.П. Фенотипы неалкогольной жировой болезни печени в различных регионах Российской Федерации, диагностические и лечебные подходы в клинической практике. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(2):7–18. DOI: 10.22416/1382-4376-2023-33-2-7-18.
DOI: 10.22416/1382-4376-2023-33-2-7-18
Mato J.M., Cámara J., Fernández de Paz J., Caballería L., Coll S., Caballero A., et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081–9. DOI: 10.1016/s0168-8278(99)80263-3.
DOI: 10.1016/s0168-8278(99)80263-3
Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;2:CD002235. DOI: 10.1002/14651858.CD002235.pub2.
DOI: 10.1002/14651858.CD002235.pub2
Lassailly G., Caiazzo R., Buob D., Pigeyre M., Verkindt H., Labreuche J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88. DOI: 10.1053/j.gastro.2015.04.014.
DOI: 10.1053/j.gastro.2015.04.014
Bower G., Toma T., Harling L., Jiao L.R., Efthimiou E., Darzi A., et al. Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9. DOI: 10.1007/s11695-015-1691-x.
DOI: 10.1007/s11695-015-1691-x
Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60.e11. DOI: 10.1016/j.cgh.2018.10.017.
DOI: 10.1016/j.cgh.2018.10.017
Fakhry T.K., Mhaskar R., Schwitalla T., Muradova E., Gonzalvo J.P., Murr M.M. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11. DOI: 10.1016/j.soard.2018.12.002.
DOI: 10.1016/j.soard.2018.12.002
Zhou H., Luo P., Li P., Wang G., Yi X., Fu Z., et al. Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis. Obes Surg. 2022;32(6):1872–83. DOI: 10.1007/s11695-022-06011-1.
DOI: 10.1007/s11695-022-06011-1
Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78. DOI: 10.1038/s41575-021-00523-4.
DOI: 10.1038/s41575-021-00523-4
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65–90. DOI: 10.1159/000443344.
DOI: 10.1159/000443344
Fernández T., Viñuela M., Vidal C., Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2022;17(2):e0263931. DOI: 10.1371/journal.pone.0263931.
DOI: 10.1371/journal.pone.0263931
Glass L.M., Hunt C.M., Fuchs M., Su G.L. Comorbidities and nonalcoholic fatty liver disease: The chicken, the egg, or both? Fed Pract. 2019;36(2):64–71.
Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881–91. DOI: 10.1038/ajg.2013.5.
DOI: 10.1038/ajg.2013.5
Ma S., Zheng Y., Xiao Y., Zhou P., Tan H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore). 2017;96(19):e6888. DOI: 10.1097/MD.0000000000006888.
DOI: 10.1097/MD.0000000000006888
Zhou Y.Y., Zhu G.Q., Liu T., Zheng J.N., Cheng Z., Zou T.T., et al. Systematic review with network meta-analysis: Antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep. 2016;6:33743. DOI: 10.1038/srep33743.
DOI: 10.1038/srep33743
Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. DOI: 10.1053/j.gastro.2012.10.005.
DOI: 10.1053/j.gastro.2012.10.005
Singal A., Volk M.L., Waljee A., Salgia R., Higgins P., Rogers M.A., et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. DOI: 10.1111/j.1365-2036.2009.04014.x.
DOI: 10.1111/j.1365-2036.2009.04014.x
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. DOI: 10.1016/j.jhep.2018.03.019.
DOI: 10.1016/j.jhep.2018.03.019
Machado M.V. The growing landscape of NAFLD-associated hepatocellular carcinoma and its impact in surveillance. GE Port J Gastroenterol. 2023;31(1):14–23. DOI: 10.1159/000531397.
DOI: 10.1159/000531397
Younossi Z., Stepanova M., Ong J.P., Jacobson I.M., Bugianesi E., Duseja A., et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55.e3. DOI: 10.1016/j.cgh.2018.05.057.
DOI: 10.1016/j.cgh.2018.05.057
Ducreux M., Abou-Alfa G.K., Bekaii-Saab T., Berlin J., Cervantes A., de Baere T., et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567. DOI: 10.1016/j.esmoop.2023.101567.
DOI: 10.1016/j.esmoop.2023.101567
Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113–21. DOI: 10.1053/j.gastro.2005.04.014.
DOI: 10.1053/j.gastro.2005.04.014
Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl. 19):89–95. DOI: 10.1007/s00535-008-2262-x.
DOI: 10.1007/s00535-008-2262-x
Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8. DOI: 10.1002/hep.23527.
DOI: 10.1002/hep.23527
Bertot L.C., Jeffrey G.P., Wallace M., MacQuillan G., Garas G., Ching H.L., et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017;1(1):53–60. DOI: 10.1002/hep4.1018.
DOI: 10.1002/hep4.1018
Than N.N., Ghazanfar A., Hodson J., Tehami N., Coldham C., Mergental H., et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2017;110(2):73–81. DOI: 10.1093/qjmed/hcw151.
DOI: 10.1093/qjmed/hcw151
Yoo J.J., Park M.Y., Cho E.J., Yu S.J., Kim S.G., Kim Y.J., et al. Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease. J Clin Med. 2023;12(9):3336. DOI: 10.3390/jcm12093336.
DOI: 10.3390/jcm12093336
Caussy C., Soni M., Cui J., Bettencourt R., Schork N., Chen C.H., et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127(7):2697–704. DOI: 10.1172/JCI93465.
DOI: 10.1172/JCI93465
Wijarnpreecha K., Thongprayoon C., Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8–12. DOI: 10.1097/MEG.0000000000000776.
DOI: 10.1097/MEG.0000000000000776
Hayat U., Siddiqui A.A., Okut H., Afroz S., Tasleem S., Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254. DOI: 10.1016/j.aohep.2020.08.071.
DOI: 10.1016/j.aohep.2020.08.071
Kennedy O.J., Roderick P., Buchanan R., Fallowfield J.A., Hayes P.C., Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis. BMJ Open. 2017;7(5):e013739. DOI: 10.1136/bmjopen-2016-013739.
DOI: 10.1136/bmjopen-2016-013739
Shen H., Rodriguez A.C., Shiani A., Lipka S., Shahzad G., Kumar A., et al. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Therap Adv Gastroenterol. 2016;9(1):113–20. DOI: 10.1177/1756283X15593700.
DOI: 10.1177/1756283X15593700
Chen Y.P., Lu F.B., Hu Y.B., Xu L.M., Zheng M.H., Hu E.D. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552–7. DOI: 10.1016/j.clnu.2018.11.030.
DOI: 10.1016/j.clnu.2018.11.030
Marventano S., Salomone F., Godos J., Pluchinotta F., Del Rio D., Mistretta A., et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr. 2016;35(6):1269–81. DOI: 10.1016/j.clnu.2016.03.012.
DOI: 10.1016/j.clnu.2016.03.012
Ebadi M., Ip S., Bhanji R.A., Montano-Loza A.J. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: Systematic review with meta-analysis of observational studies. Nutrients. 2021;13(9):3042. DOI: 10.3390/nu13093042.
DOI: 10.3390/nu13093042
Birerdinc A., Stepanova M., Pawloski L., Younossi Z.M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(1):76–82. DOI: 10.1111/j.1365-2036.2011.04916.x.
DOI: 10.1111/j.1365-2036.2011.04916.x
Inoue M., Yoshimi I., Sobue T., Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst. 2005;97(4):293–300. DOI: 10.1093/jnci/dji040.
DOI: 10.1093/jnci/dji040
Johnson S., Koh W.P., Wang R., Govindarajan S., Yu M.C., Yuan J.M. Coffee consumption and reduced risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22(3):503–10. DOI: 10.1007/s10552-010-9725-0.
DOI: 10.1007/s10552-010-9725-0
Hu G., Tuomilehto J., Pukkala E., Hakulinen T., Antikainen R., Vartiainen E., et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008;48(1):129–36. DOI: 10.1002/hep.22320.
DOI: 10.1002/hep.22320
Tanaka K., Hara M., Sakamoto T., Higaki Y., Mizuta T., Eguchi Y., et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: A case-control study in Japan. Cancer Sci. 2007;98(2):214–8. DOI: 10.1111/j.1349-7006.2006.00368.x.
DOI: 10.1111/j.1349-7006.2006.00368.x